🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines in the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Agency leaders were set to reveal major changes to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s national calendar, according to reports – a major change that would place the US at odds with a large portion of the international standard with insufficient data for benefit. This reveal has been pushed back until the next year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some childhood shot schedules in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – typically the responsibility of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

Høeg has little discernible experience in drug development, oversight or management, which has been customary for former heads of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

CDER has an immense portfolio at the agency, the former commissioner emphasized.

“Everybody just zeroes in on the new drug program, but the generic drug division clears numerous generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those need to be managed,” Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the position, which manages more than 5,000 staff members. “It’s a enormous management job, if you do it right,” the former official concluded.

Official Statement and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this appointment signifies more teamwork among agency officials on immunizations, a representative responded that the “questions are based on flawed premises”.

“Her resume is consistent with the functions of her job,” the official said, noting the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a disputed rapid therapy clearance system that reportedly concerned her former heads. “By what process are these medications being picked for this expedited pathway? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards more relaxed rules of pharmaceuticals, aside from immunizations.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if problematic, past, critics observe. She released a study using non-validated public submissions to estimate the rate of myocarditis after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the current administration featured revising regulations for recently developed shots and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing young men from getting Covid vaccinations.

“She’s an all-around dogmatist who begins with her conclusions and reverse-engineers to retrofit the data in a very misleading, dishonest fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|